Runs — Nemotron

{
  "market_summary": "Market mixed with Nasdaq sliding on chip weakness and Iran concerns while Dow/S&P recover on easing oil. Big earnings-driven moves: RNG +25%, THC +18%, BAH/SSNC/CLF +10% on beats; chip names (MXL, AEHR, NVDA, MU) selling off hard. Rotation out of AI/tech into energy, industrials, financials.",
  "decisions": [
    { "action": "SELL", "ticker": "RNG", "shares": 2, "reasoning": "RingCentral surged 25% today on Q2 beat and 67% dividend hike, taking 1M gain to 39%. The 2-share position ($96.81) has become extended short-term; locking in profits frees $96.82 for redeployment into less crowded names while maintaining 8-position count." },
    { "action": "BUY", "ticker": "SLB", "shares": 1, "reasoning": "SLB (Schlumberger) up 10.4% today with 8.7% 1M momentum as oil services benefit from global upstream spending resilience. At $52.12, one share fits the small-account budget, adds energy exposure diversifying from tech/financials, and stays well under the 15% position cap." },
    { "action": "BUY", "ticker": "AMBP", "shares": 13, "reasoning": "Ardagh Metal Packaging beat Q2 estimates, raised guidance, and pays a $0.10 dividend. At $4.83 the stock is 6.8% below our $5.18 cost but up 7.2% over the past month. Adding 13 shares ($62.79) averages down, builds a meaningful 28-share ($135.24) position still under the $143.44 limit, and leverages the low share price for sizing flexibility." }
  ],
  "watch_notes": "Monitor RNG for pullback entry if thesis holds; watch INTC ($93) and NOK ($9) for value traps vs turnaround; track THC ($236) and DLR ($199) for future buys if cash builds; AMBP earnings momentum and SLB oil-cycle exposure are key near-term drivers."
}

{
  "sell": [
    {
      "ticker": "RNG",
      "shares": 2,
      "reason": "Take profits after 40% 1-month run and 26% single-day surge on earnings; small position (2 shares) at 10% of portfolio with elevated valuation risk in volatile tech"
    }
  ],
  "buy": [
    {
      "ticker": "T",
      "shares": 1,
      "reason": "Defensive telecom with earnings beat, dividend yield, and CEO pushing back on Starlink competition; adds 1 share to bring position to 14.9% (near 15% cap)"
    },
    {
      "ticker": "AMBP",
      "shares": 13,
      "reason": "Packaging play with recent earnings beat and raised guidance; up 7.8% 1M despite recent pullback; 13 shares adds $63 at $4.85, bringing position to 14.2% of portfolio"
    }
  ]
}

{
  "market_summary": "Markets are mixed with Dow rising on easing oil prices and Intel gains, while Nasdaq slips on tech weakness. Earnings season is driving significant single-stock moves — RingCentral (+27%), Tenet Healthcare (+22%), and Booz Allen (+14%) surging on strong results, while MaxLinear (-18%) and several AI/semiconductor names sell off despite beats. Breadth appears bifurcated between earnings winners and rate-sensitive growth.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "NVCR",
      "shares": 7,
      "reasoning": "NVCR is the portfolio's worst performer (-8.3% today, -8.3% overall) and the thesis appears broken. Headlines note 'Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding,' suggesting fundamental improvement isn't translating to price action. The 34% 1M gain has fully reversed in a single session, indicating distribution. Selling 7 shares at ~$18.33 raises $128.31, removes a losing position, and frees capital for higher-conviction ideas."
    },
    {
      "action": "SELL",
      "ticker": "ORKA",
      "shares": 1,
      "reasoning": "ORKA is a 1-share position worth only $93.12 (9.7% of equity) — too small to matter for performance but still consumes a position slot. With 7 of 10 slots used, eliminating this micro-position improves portfolio efficiency. The stock is up modestly (+0.45% overall, +9% 1M) but lacks momentum versus today's big earnings-driven movers. Proceeds of $93.12 fund better opportunities."
    },
    {
      "action": "BUY",
      "ticker": "RNG",
      "shares": 2,
      "reasoning": "RingCentral reported strong Q2 earnings with revenue growth and improving profitability, driving a 27% single-day surge and 40% 1M gain. At $49.05, 2 shares cost $98.10 (10.3% of equity), well under the 15% cap. The beat-and-raise dynamic, plus non-engineers building software with OpenAI tools, suggests AI-driven operating leverage. Momentum and fundamentals align for a 2-share starter position."
    },
    {
      "action": "BUY",
      "ticker": "BAH",
      "shares": 1,
      "reasoning": "Booz Allen Hamilton surged 14% on Q1 FY27 earnings that easily beat estimates while maintaining guidance. Government consulting offers recession-resistant revenue visibility. At $75.18, 1 share uses 7.9% of equity. The 18% 1M gain shows sustained institutional interest. Adding a high-quality compounder with today's momentum diversifies away from cyclical/industrial exposure in CLF and EQNR."
    },
    {
      "action": "BUY",
      "ticker": "SSNC",
      "shares": 1,
      "reasoning": "SS&C Technologies delivered record Q2 results with sales and earnings beats, driving an 11% pop. The stock trades at $74.35 (7.8% of equity for 1 share). As a financial software consolidator with recurring revenue, it offers defensive growth. Needham maintains a $90 price target (~21% upside). This adds a steady compounder to balance the portfolio's more volatile names."
    }
  ],
  "watch_notes": "Monitor NVCR for any reversal confirmation before considering re-entry. Watch RNG volume for follow-through on earnings momentum. Track BAH and SSNC for guidance updates. Keep an eye on MXL (-18% despite Q2 beat) for potential value entry if selling exhausts. CLF and EQNR remain small losers; reassess if steel/oil fundamentals deteriorate."
}

{
  "market_summary": "Markets are mixed with Dow futures rebounding as oil eases, but AI capex concerns and rising yields weigh on sentiment. Notable divergence: defensive/value names like THC, RNG, BAH, DLR, and CLF are surging on earnings beats, while semiconductor and tech names (MXL, AAOI, NBIS, CBRS) are selling off sharply. Financials and industrials show relative strength.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "EQPT",
      "shares": 6,
      "reasoning": "EQPT has collapsed 28.66% over the past month and dropped another 4.5% today. The thesis is broken: a short report has sparked legal questions and the stock is making lower lows on high volume. Despite a recent revenue outlook hike, the market clearly doesn't trust the narrative. Holding a $111 position that's bleeding capital in a small account is indefensible — cut the loss and redeploy into names with positive momentum."
    },
    {
      "action": "SELL",
      "ticker": "SMCI",
      "shares": 4,
      "reasoning": "SMCI is down 14.95% over the past month and 3.3% today despite headlines about a gross margin raise and $60B backlog. The price action contradicts the news — a classic 'sell the news' or distribution pattern. Legal/regulatory overhang (previously disclosed) continues to suppress the multiple. At $30.16, the risk/reward no longer favors holding a $120 position that's underperforming the broader market and sector peers."
    },
    {
      "action": "BUY",
      "ticker": "CLF",
      "shares": 12,
      "reasoning": "Cleveland-Cliffs is a top day gainer (+7.85%) on heavy volume, signaling institutional accumulation. As a domestic steel producer, it benefits from infrastructure spending, tariff protection, and auto-sector demand. The stock is cheap at $11.82 (near 52-week lows), offering a 14.7% portfolio position ($141.84) that respects the 15% cap. Monthly performance is flat (-0.59%), suggesting a base is forming. This is a high-conviction cyclical turnaround play with a clear catalyst path."
    }
  ]
}

{
  "market_summary": "Markets are selling off sharply as mega-cap tech (TSLA -14.8%, GOOGL -7.1%, NVDA -2%) cracks under AI capex skepticism, rising oil ($100/bbl), and higher bond yields. Defensive and energy names (EQNR +2.9%, NVCR +27.9%) are outperforming while small-caps and industrials show mixed breadth. The rotation suggests risk-off positioning ahead of potential August volatility.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "PATH",
      "shares": 10,
      "reasoning": "UiPath's thesis has deteriorated: RPA is being disrupted by generative AI agents, UBS just trimmed its price target, and the stock has delivered only +0.24% over the past month while declining 3.8% today on heavy volume. With 10 positions max and capital scarce, this consistent laggard no longer deserves a slot. Proceeds ($102.90) fund a higher-conviction infrastructure play."
    },
    {
      "action": "BUY",
      "ticker": "EQPT",
      "shares": 6,
      "reasoning": "EquipmentShare (EQPT) is a direct beneficiary of the data-center and infrastructure capex supercycle — renting heavy equipment to builders of AI factories, power projects, and reshoring plants. Today's +12% surge on volume signals institutional accumulation after a -26% 1M overshoot, creating a favorable risk/reward. At $19.43, six shares ($116.58) fit the 15% position cap ($146.22) and leave cash above the 5% floor. The recurring-revenue rental model and exposure to non-tech hard-asset spending provide portfolio diversification away from the AI software names under pressure."
    }
  ],
  "watch_notes": "Monitor NVCR for profit-taking after +28% day (risk of short-term exhaustion). Watch SMCI margin sustainability after gross-margin raise. Track oil/service names (EQNR, LBRT JV news) for energy-infrastructure follow-through. ACI's -23% plunge on weak guidance warrants sector-level caution on consumer staples."
}

{
  "market_summary": "Markets are selling off broadly on rising oil, bond yields, and AI capex skepticism, with the Magnificent 7 losing $767B. Tech earnings are testing fragile sentiment, while shorts are at record levels. However, select names like SMCI, NVCR, and ALLE are surging on strong fundamentals, showing a bifurcated market rewarding earnings quality over hype.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "OUST",
      "shares": 3,
      "reasoning": "OUST has dropped 17.7% over the past month and 4.45% today on news of a share offering that dilutes holders. The counter-drone partnership headlines haven't translated to price stability, and the thesis of near-term revenue inflection appears broken. At $38.31, the position is underwater (-4.45%) with deteriorating momentum; exiting frees $114.93 for redeployment into stronger setups."
    },
    {
      "action": "SELL",
      "ticker": "IREN",
      "shares": 3,
      "reasoning": "IREN is down 31.5% over the past month despite today's AI-data-center hype. The extreme volatility (bitcoin-mining pivot to AI) makes position sizing and risk management nearly impossible in a $1K account. The 3-share lot is too small to matter if it works, but the drawdown signals a broken trend. Selling at $41.09 recovers $123.27 and removes a high-beta distraction."
    },
    {
      "action": "BUY",
      "ticker": "NVCR",
      "shares": 7,
      "reasoning": "NovoCure reported Q2 revenue up 16% to $183.6M with new approvals, and headlines ask if it has 'turned a corner.' The stock is up 40% in a month but only 28% today, suggesting the move is earnings-driven not purely speculative. At $19.99, 7 shares ($139.93) fit the 15% position cap ($147.27) and the small-account whole-share constraint. Tumor-treating fields have a durable IP moat, and the recent revenue inflection could sustain a multi-quarter rerating."
    },
    {
      "action": "BUY",
      "ticker": "T",
      "shares": 5,
      "reasoning": "AT&T offers defensive telecom exposure with a 5.6% dividend yield, low beta, and a 4.4% 1-month gain while tech melts down. At $22.98, 5 shares ($114.90) stay well under the position cap and diversify the portfolio away from pure tech/beta. The balance sheet is improving post-WBD spin, and free cash flow covers the dividend comfortably. This adds ballast and income without sacrificing liquidity."
    }
  ],
  "watch_notes": "Monitor NVCR follow-through on volume — if today's gap holds above $20, it confirms institutional sponsorship. Watch SMCI's $60B backlog commentary for AI infrastructure durability. Keep an eye on PATH (UiPath) for any sign of enterprise automation demand stabilization before considering adding. Cash will be ~$64 post-trades, comfortably above the 5% floor."
}

{
  "market_summary": "Market mixed with notable divergence: NVCR +24.6% on strong Q2 earnings, SSL +7.5%, RTX +7.8%, while TSLA -14.2%, GOOGL -6.9%, ACI -24.1%. Portfolio at $979.38 equity with $81 cash (8.3%). OUST (-19% 1M) and PATH (-2% unrealized, UBS PT cut) are laggards. NVCR and SSL show strong momentum at affordable prices (<$146.91 position limit).",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "OUST",
      "quantity": 3,
      "reason": "Down 19% 1M, -6% unrealized, share offering dilutes holders. Thesis broken. Free $112.92 for redeployment."
    },
    {
      "action": "SELL",
      "ticker": "PATH",
      "quantity": 10,
      "reason": "Down 2.6% today, UBS trimmed PT to $14, -2% unrealized. Weak momentum. Free $104.20 for redeployment."
    },
    {
      "action": "BUY",
      "ticker": "NVCR",
      "quantity": 7,
      "reason": "Q2 earnings beat: revenue +16% to $183.6M, new approvals. +24.6% today on volume. $19.40/share allows 7 shares ($135.80) under 15% cap. Strong momentum + fundamentals."
    },
    {
      "action": "BUY",
      "ticker": "SSL",
      "quantity": 9,
      "reason": "+7.5% today, +13% 1M, $12.17/share allows 9 shares ($109.53) under cap. Sasol benefiting from energy/chemical tailwinds. Good risk/reward at this level."
    }
  ],
  "watch_notes": "Watch INTC ($101) for CHIPS Act catalysts but 1M -25%. EQT ($54) steady +6.6% 1M. MMYT ($49) +5.3% 1M travel recovery. Keep cash ~$53 (5.4%) above 5% floor. Monitor NVCR follow-through and SSL momentum."
}

{
  "market_summary": "Markets are digesting mixed tech earnings with AI capex concerns weighing on megacaps (GOOGL -5.86%, TSLA -10.71%), while defensive sectors and energy show strength. Small-caps and beaten-down names are seeing rotation as investors hedge AI concentration risk.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "INTC",
      "shares": 1,
      "reasoning": "Intel's turnaround thesis has failed — down 23.84% over the past month with earnings imminent but no credible path to AI relevance. The Ohio fab partnership search signals desperation, not strength. Better to exit and redeploy into companies with visible growth catalysts."
    },
    {
      "action": "SELL",
      "ticker": "ACMR",
      "shares": 1,
      "reasoning": "ACM Research is caught in the semiconductor equipment downcycle, down 18.22% in a month with no near-term catalyst. China exposure adds geopolitical risk. The position is small (1 share) and the thesis has deteriorated; proceeds fund higher-conviction ideas."
    },
    {
      "action": "BUY",
      "ticker": "AMBP",
      "shares": 15,
      "reasoning": "Ardagh Metal Packaging offers a 7%+ dividend yield backed by stable beverage can volumes and sustainability-driven aluminum substitution. Q2 earnings beat and raised guidance confirm operational momentum. At $5.18, 15 shares ($77.70) fit well under the 15% position cap and add defensive income."
    },
    {
      "action": "BUY",
      "ticker": "EQNR",
      "shares": 3,
      "reasoning": "Equinor combines a 4%+ dividend with a credible energy transition strategy (offshore wind, CCS) while benefiting from tight gas markets. Up 27% in a month on strong execution. Three shares ($123.72) provide energy diversification without exceeding position limits."
    },
    {
      "action": "BUY",
      "ticker": "PATH",
      "shares": 10,
      "reasoning": "UiPath is the RPA leader pivoting to AI-powered automation — a structural growth market. Shares are beaten down (-14% 1M) but fundamentals are improving with cloud ARR growth. Ten shares ($106.30) establish a position at a reasonable entry point for a long-term compounder."
    },
    {
      "action": "BUY",
      "ticker": "SMCI",
      "shares": 1,
      "reasoning": "Supermicro remains the premier AI server play with a $60B backlog and rising gross margins. Adding one share ($30.74) brings the position to 4 shares ($122.96), still under the 15% cap, reinforcing a high-conviction winner in the core AI infrastructure theme."
    }
  ],
  "watch_notes": "Monitor NU for Mexico banking license ramp (add on pullback if under $14), OUST for counter-drone contract conversion (sell if dilution continues), and IREN for AI data center revenue proof points. Watch SMCI earnings next week for margin sustainability. Keep dry powder for any broad market sell-off on AI capex fears."
}

{
  "market_summary": "Markets are mixed with the S&P 500 flat as traders brace for Alphabet and Tesla earnings after the close. Oil near $95 is lifting energy names while AI capex euphoria drives SMCI to a 20% surge on a $60B backlog. Conversely, enterprise software is cracking — PATH down 12% on a UBS price-target cut — signaling potential fatigue in automation spending.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "PATH",
      "shares": 13,
      "reasoning": "UiPath gapped down 12% today after UBS trimmed its price target, citing slowing enterprise automation budgets and elongated sales cycles. The thesis of durable high-growth RPA adoption is fracturing; the stock has now broken below its 50-day average on heavy volume. With only a 0.45% unrealized loss but clear technical and fundamental deterioration, exiting the full 13-share position (~$137) preserves capital and frees a slot for higher-conviction ideas."
    },
    {
      "action": "SELL",
      "ticker": "GLXY",
      "shares": 5,
      "reasoning": "Galaxy Digital has shed nearly 25% over the past month despite a modest 5% gain on our cost basis. The crypto/blockchain narrative remains hostage to Bitcoin volatility and regulatory overhang, and the upcoming Q2 print (Aug 5) carries more downside risk than upside given the recent digital-asset rout. The 5-share lot (~$124) is small but the opportunity cost is high — proceeds are better redeployed into secular growers with cleaner catalysts."
    },
    {
      "action": "BUY",
      "ticker": "INTC",
      "shares": 1,
      "reasoning": "Intel trades at $103.98, down 14% in a month, offering a rare single-share entry under our $148 position cap. CHIPS Act funding, foundry progress, and a potential foundry spin-off provide multiple catalysts. Downside is cushioned by tangible book value and a 1.5% yield. One share (~$104) fits the position cap and adds a deep-value, optionality-rich name to the portfolio."
    }
  ]
}

{
  "market_summary": "Markets are mixed with chip stocks leading gains on AI optimism (NVDA +3.25%, AMD +2.23%, SMCI +22%) while big tech earnings (Alphabet, Tesla, Intel) loom after hours. Oil near $95 adds inflation pressure. The S&P 500 snapped a three-day losing streak but breadth remains narrow.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "INTC",
      "shares": 1,
      "reasoning": "Intel reports Q2 earnings today with the stock down 13.5% over the past month. The single-share position ($104.70) offers minimal upside relative to binary earnings risk, and proceeds can be redeployed into a stronger AI infrastructure name with better momentum."
    },
    {
      "action": "BUY",
      "ticker": "SMCI",
      "shares": 3,
      "reasoning": "Supermicro surged 22% today on a gross margin raise and a record $60B backlog, confirming massive AI server demand. At $31.18, three shares ($93.54) fit well under the 15% position cap ($149.47) and leave ample cash above the 5% floor. This adds a high-conviction AI infrastructure play with fundamental catalysts rather than chasing pure momentum."
    }
  ],
  "watch_notes": "Monitor INTC earnings reaction for sector cues; watch PATH for stabilization after -13% drop (UBS cut vs. '40% undervalued' claim); track SMCI follow-through and NVDA/AMD momentum; observe oil/geopolitical headlines for broad market impact."
}

{
  "market_summary": "Mixed market with strong momentum in AI infrastructure (SMCI +24%, ARWR +22%) and biotech, while software names like PEGA (-15%) and PATH (-12%) sell off on earnings/guidance concerns. Crypto names (GLXY, RIOT, IREN) volatile with IREN showing strong AI contract momentum (+$2.8B contracts). Gold miners (AYA, ORLA, CDE) and uranium (NG) showing strength. Semiconductors mixed with INTC flat ahead of earnings, SMCI surging on $60B backlog. Portfolio holds 8 positions with $99.46 cash (9.9% equity), all positions under 15% limit. COAG (+84% 1M) shows extreme momentum in biotech; ACMR (-3.2% from cost) lagging semis.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "COAG",
      "shares": 2,
      "reason": "Take profits on 84% 1-month surge in speculative biotech (Hemab Therapeutics). Position small (2 shares, $97) but extended technically; locking in gains reduces biotech concentration risk and frees $97.48 cash for redeployment."
    },
    {
      "action": "BUY",
      "ticker": "PATH",
      "shares": 13,
      "reason": "UiPath oversold 12% today despite headlines citing 40% undervaluation on fresh AI contract wins. AI automation tailwind intact; 13 shares at ~$10.59 = ~$137.67 fits position limit ($150.73) and deployable cash ($146.70 post-COAG sale). Risk/reward favorable on oversold quality AI name."
    }
  ],
  "watch_notes": "SMCI (+24% today) extended short-term; watch for pullback to $28-30 for entry. IREN holding strong on $2.8B AI contracts; monitor for add on dips. Gold miners AYA/ORLA/CDE showing momentum with gold strength. PEGA (-15%) potential value trap until AI demand clarity. INTC earnings imminent - monitor for portfolio impact. ACMR monitor for semis cycle turn."
}

{
  "sell": [
    {
      "ticker": "INTC",
      "shares": 1,
      "reason": "Struggling semiconductor with secular CPU share loss, upcoming earnings risk, down 13.5% in 1M. Thesis broken; better opportunities elsewhere."
    }
  ],
  "buy": [
    {
      "ticker": "SMMT",
      "shares": 10,
      "reason": "Summit Therapeutics: biotech with ivonescimab (PD-1/VEGF bispecific) showing positive Phase 3 data in NSCLC. Strong 1M momentum (+5.2%), $14.85/share allows 10-share position ($148.50) under 15% concentration limit. Positive catalyst trajectory."
    }
  ],
  "hold": [
    "ACMR",
    "COAG",
    "GLXY",
    "IREN",
    "NU",
    "ORKA",
    "OUST"
  ],
  "cash_after_trades": 55.65
}

{
  "market_summary": "Market is mixed with chip stocks leading gains (AEHR +26.5%, semis broadly higher) while Jamie Dimon warns of underestimated risks. Crypto-mining and AI infrastructure names are volatile. Our portfolio shows heavy concentration in speculative tech/crypto names with several positions underwater on a 1-month basis.",
  "decisions": [
    { "action": "SELL", "ticker": "CIFR", "shares": 5, "reasoning": "Cipher Mining is down 12.9% over the past month and the bitcoin mining thesis continues to deteriorate with hashprice pressure and no clear catalyst for recovery. The 11% daily bounce appears technical, not fundamental. Cutting this loser frees $114.10 and removes a broken thesis from the portfolio." },
    { "action": "SELL", "ticker": "AEHR", "shares": 1, "reasoning": "Aehr Test Systems surged 26.5% today on record bookings earnings, but the stock is only 0.36% above our cost basis. The valuation leaves little room for error per Seeking Alpha, and the parabolic move suggests short-term exhaustion. Taking the small profit ($0.35) and redeploying into better risk/reward setups." },
    { "action": "BUY", "ticker": "INTC", "shares": 1, "reasoning": "Intel trades at $105.55 with new leadership, foundry progress, and potential CHIPS Act tailwinds. Today's 8.75% jump on above-average volume suggests institutional accumulation. At 1 share ($105.55), it fits the 15% position cap and offers asymmetric upside if the turnaround executes, with downside cushioned by asset value." },
    { "action": "BUY", "ticker": "ACMR", "shares": 1, "reasoning": "ACM Research ($94.69) is a semiconductor equipment play benefiting from China's aggressive fab buildout and US/ally capacity expansion. Up 14.75% today with strong 1-month momentum (+3.86%). Single share keeps position size disciplined while adding semi-cap-ex exposure complementary to our AEHR exit." },
    { "action": "BUY", "ticker": "OUST", "shares": 3, "reasoning": "Ouster ($40.09) announced a counter-drone partnership with ARGUS, tapping the fast-growing physical AI/defense lidar market. Up 15.34% today on volume. Three shares ($120.27) builds a meaningful starter position under the 15% cap, diversifying away from pure crypto/AI compute into robotics/defense autonomy." }
  ],
  "watch_notes": "Monitor INTC for 10-Q guidance and foundry customer announcements; watch ACMR for China revenue trajectory; track OUST for defense contract conversions. Also watching NU (already held) for Mexico/Brazil loan growth, and TENB/FIG for potential oversold bounces if market stabilizes. Maintain 5% cash floor."
}

{
  "market_summary": "Markets are mixed with chip stocks leading gains (AEHR +26%, MU +13%, AMD +8%) while biotech and software names sell off. The AI infrastructure theme remains dominant but shows signs of rotation — semiconductor test/capital equipment (AEHR) and data center plays (CIFR, IREN) are outperforming, while recent high-flyers in software (MSCI, QLYS, TEAM) correct sharply. Jamie Dimon's cautionary comments on valuations add macro uncertainty.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "TRVI",
      "shares": 7,
      "reasoning": "TRVI is the only position with an unrealized loss (-5.5% vs cost) despite a +17% 1-month return, indicating significant giveback of prior gains. Today's +7.45% pop on BMO initiation and B. Riley positivity looks like a news-driven relief rally rather than fundamental improvement. The Haduvio cough franchise remains binary and early-stage; with the thesis weakening and better opportunities in AI infrastructure, I'm cutting this loser to free $126.14 for redeployment."
    },
    {
      "action": "BUY",
      "ticker": "AEHR",
      "shares": 1,
      "reasoning": "AEHR reported record Q4 bookings and $100M effective backlog, driving a 26% surge on heavy volume. As the sole provider of wafer-level burn-in for AI accelerators, it sits at a critical bottleneck in the semiconductor supply chain. At $97.55, one share fits well under the $152.72 position cap and adds high-conviction AI infrastructure exposure with tangible earnings momentum, unlike the speculative crypto/AI pivots elsewhere."
    },
    {
      "action": "BUY",
      "ticker": "CIFR",
      "shares": 5,
      "reasoning": "CIFR is surging 17.5% ahead of Q2 earnings on growing hedge fund interest and its AI data center pivot narrative. At $24.14, five shares ($120.70) stay under the position cap and provide levered exposure to both bitcoin mining optionality and the high-margin HPC hosting transition. The stock's -7.9% 1-month return suggests this move may be early, and the earnings catalyst provides a near-term milestone."
    }
  ],
  "watch_notes": "Monitor AEHR's backlog conversion and CIFR's earnings for HPC contract updates. Watch IREN's AI deal pipeline for further upside. NU's Mexico license progress and GLXY's BitLicense approval are positive but need price follow-through. INTC ($104.92) and MXL ($85.40) are on radar for semiconductor breadth if rotation continues."
}

{
  "sell": [
    {
      "ticker": "GLXY",
      "shares": 5,
      "reason": "Down 22.39% 1M with bearish analyst commentary (BitLicense achieved but stock sliding, bearish Leopold Aschenbrenner commentary). Position near 15% limit with deteriorating momentum."
    }
  ],
  "buy": [
    {
      "ticker": "AEHR",
      "shares": 1,
      "reason": "Record bookings, $100M backlog, +25.6% day on fundamental strength. AI test equipment beneficiary. 1 share = $97.19 (<15% limit)."
    },
    {
      "ticker": "CIFR",
      "shares": 5,
      "reason": "AI data center pivot with major contracts, +15.5% day ahead of Q2 earnings. 5 shares = $118.10 (<15% limit). Strong neocloud momentum."
    },
    {
      "ticker": "MAAS",
      "shares": 3,
      "reason": "Strong momentum: +12.3% day, +26.8% 1M. 3 shares = $60.42. Small-cap momentum play with room to run."
    },
    {
      "ticker": "TENB",
      "shares": 2,
      "reason": "Strong 1M performance (+30.8%) pulling back -6.7% today. Tenable cybersecurity fundamentals. 2 shares = $70.46. Dip buy on uptrend."
    }
  ]
}

{
  "market_summary": "Market opens with chip stocks leading gains (NVDA +2.4%, AMD +4.6%, INTC +6.4%) on AI optimism, while biotech and crypto names show mixed action. Nasdaq futures higher but breadth appears narrow with mega-cap tech driving indices. Earnings season intensifies this week with INTC reporting Thursday.",
  "decisions": [],
  "watch_notes": "Monitoring INTC earnings Thursday for turnaround signals; TRVI progression toward BMO $36 target vs $17 current. Watching CIFR Q2 earnings for AI data center revenue traction. Tracking IREN/GLXY/HUT data center expansion news. COAG clinical catalysts and ORKA pipeline updates remain key for biotech holdings."
}

{
  "market_summary": "Nasdaq leads gains as chipmakers rebound, but market breadth is narrow with Mag 7 leadership fading and S&P 500 flashing dot-com-era warning signs. Crypto/compute infrastructure names (IREN, GLXY, MARA) are volatile on AI data-center demand headlines, while biotechs (COAG, ORKA, TRVI) show momentum on pipeline catalysts. China's national team buying and Korea margin-loan risks add macro uncertainty.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "INTC",
      "shares": 1,
      "reasoning": "Intel has declined 23% over the past month and remains in a semiconductor sector correction ahead of Q2 earnings. The single-share position ($97.92) is too small to matter for diversification but ties up capital that can be redeployed into higher-conviction names with better momentum and clearer catalysts. Selling frees $97.92 for immediate reuse this cycle."
    },
    {
      "action": "BUY",
      "ticker": "GLXY",
      "shares": 5,
      "reasoning": "Galaxy Digital offers levered exposure to the bitcoin/AI compute convergence theme that drove IREN up 18.7% today on the CoreWeave partnership. GLXY trades at a discount to NAV, holds a large BTC treasury, and operates mining/hosting infrastructure that benefits from the same AI/HPC colocation demand. At ~$18.50/share, 5 shares costs ~$92.50, fits within the $97.92 freed from INTC, and provides asymmetric upside on the bitcoin/AI convergence thesis."
    }
  ]
}

{
  "market_summary": "Markets are mixed with chipmakers and AI-exposed names leading gains while financials and some biotech lag. The S&P 500 and Nasdaq are higher as oil wavers. Notable movers include IREN surging 20% on AI cloud contract wins, AMC jumping 26% on record earnings, and SNEX plunging 32% on a downgrade. Chinese market stabilization efforts and AI infrastructure spending themes dominate headlines.",
  "decisions": [
    {
      "action": "SELL",
      "ticker": "COAG",
      "shares": 1,
      "reasoning": "COAG has nearly doubled (+98% 1M) and sits at $149.00, just $0.53 below the 15% single-position cap of $149.53. Selling one share locks in substantial gains, reduces concentration risk, and frees $49.66 for redeployment while leaving a still-meaningful 2-share position (~$99) well within limits. The coagulation franchise thesis remains intact but position discipline demands trimming at this level."
    },
    {
      "action": "BUY",
      "ticker": "IREN",
      "shares": 1,
      "reasoning": "IREN surged 20% on AI cloud contract wins, validating its pivot to high-margin AI infrastructure. At $13.80 it remains well below the 15% position cap, leaving ample room for a starter position. The AI infrastructure buildout thesis is accelerating, and IREN's power-secured data center portfolio positions it as a key enabler. A 1-share starter position (~$13.80) establishes exposure with room to add on pullbacks."
    },
    {
      "action": "BUY",
      "ticker": "IREN",
      "shares": 1,
      "reasoning": "Adding a second share of IREN at ~$13.80 increases the starter position to ~$27.60, still well within the 15% position limit. The AI infrastructure buildout thesis is accelerating with major contract wins, and IREN's power-secured data center portfolio provides a durable moat. Adding a second share now builds a meaningful starter position while maintaining ample room to add on pullbacks."
    }
  ]
}

{
  "market_summary": "Markets are mixed with Nasdaq/S&P edging higher amid Middle East oil concerns and China stimulus. Biotechs show momentum (COAG, ORKA, TRVI up big 1M) while semiconductors are divergent (MU +4%, AMD +3.5%, but INTC -23% 1M). Crypto/AI infrastructure names like IREN (+16% today) and MARA (+9.6%) are catching bids on AI cloud narratives.",
  "decisions": [
    {
      "action": "BUY",
      "ticker": "IREN",
      "shares": 3,
      "reasoning": "IREN surged 16% today on announced AI cloud contract wins that lifted its annual revenue target, signaling successful pivot from pure Bitcoin mining to high-margin AI infrastructure. Despite a 35% 1M decline, today's volume and news flow suggest institutional recognition of the re-rate. At $39.07, 3 shares ($117.21) fits well under the $149.49 position cap and adds non-biotech, non-megacap diversification with a clear catalyst-driven thesis."
    },
    {
      "action": "BUY",
      "ticker": "NU",
      "shares": 10,
      "reasoning": "Nu Holdings continues its steady ascent (+12.6% 1M, +3% today) as Brazil's dominant digital bank expands into Mexico and Colombia with improving credit quality and rising ARPU. The fintech trades at a reasonable multiple for 30%+ revenue growth, profitable, and with a massive underbanked addressable market. 10 shares at $14 ($140 total) stays under the position cap and provides LatAm consumer exposure uncorrelated to current biotech-heavy holdings."
    },
    {
      "action": "BUY",
      "ticker": "INTC",
      "shares": 1,
      "reasoning": "Intel at $98.36 (down 23% 1M) offers a deep-value semiconductor play with foundry optionality (CHIPS Act, 18A process) and a new CEO focused on execution. Today's +3.5% move on above-average volume may signal bottom-fishing. A single share ($98.36) is a low-risk toehold that keeps powder dry; if the turnaround thesis plays out, the asymmetric upside justifies the small allocation."
    }
  ],
  "watch_notes": "Monitor TRVI's -6.35% daily drop — if it breaks below $17 support on volume, the 1M uptrend may be threatened and a stop-loss could trigger. Watch COAG for profit-taking after 102% 1M run; a pullback to $48-49 would be a healthier entry for adding. Track IREN's follow-through on AI cloud revenue conversion and NU's Q2 earnings (likely early August) for loan growth and NIM trends."
}

{
  "sell": [],
  "buy": []
}

{
  "market_summary": "The market is closed, with fills based on last close prices. Recent trading saw a mixed performance, with some biotech and energy names rising while tech stocks, particularly semiconductors like NVDA and AMD, faced declines. Geopolitical and macroeconomic concerns linger, but certain catalyst-driven stocks like ORKA and LCID show strength.",
  "decisions": [
    {
      "action": "BUY",
      "ticker": "ORKA",
      "shares": 1,
      "reasoning": "Oruka Therapeutics (ORKA) is experiencing upward momentum following positive psoriasis trial results and a significant analyst price target hike (BTIG +94%). The stock is in an uptrend with strong volume, aligning with its cash runway and pipeline focus. At $92.70 per share, a 1-share position ($92.70) fits within the $150 max position limit. This represents a high-conviction move into a catalyst-driven biotech with near-term potential, using available cash while maintaining portfolio diversification."
    }
  ],
  "watch_notes": "Monitoring existing positions COAG and TRVI for any post-close news or gap risk given the market's closed status. Also tracking LCID and SLS for potential entry if they stabilize or show renewed strength, while watching tech sector weakness (NVDA, MSFT) for broader market implications."
}

{
  "market_summary": "The market is closed, with fills based on last close prices. Tech and AI stocks face pressure, while biotech and energy names show strength. Day gainers like LCID, COAG, and TRVI stand out, but high volatility and stale data warrant caution.",
  "decisions": [
    {
      "action": "BUY",
      "ticker": "COAG",
      "shares": 3,
      "reasoning": "Hemab Therapeutics (COAG) presents a compelling entry point with multiple clinical catalysts and a strong cash position. Recent positive study results (72% of patients 40+ still bleeding weekly) and Jefferies' raised price target to $47 underscore its potential. The stock’s 10.69% gain today aligns with fundamentals, and purchasing 3 shares at $49.29 each ($147.87 total) stays within the 15% position cap, offering exposure to a cash-rich coagulation franchise with near-term upside."
    },
    {
      "action": "BUY",
      "ticker": "TRVI",
      "shares": 7,
      "reasoning": "Trevi Therapeutics (TRVI) is poised for growth following GSK’s exit from the chronic cough therapy space, reducing competition for its Haduvio drug. The stock’s 9.85% surge today reflects improved market positioning, and buying 7 shares at $19.07 ($133.49 total) capitalizes on this catalyst while adhering to the $150 position limit. Analyst confidence and the drug’s potential in an underserved market support this high-conviction buy."
    }
  ],
  "watch_notes": "Monitor COAG for upcoming clinical trial updates and TRVI for further competitive dynamics in the cough therapy market. Also track LCID’s volatility post-bankruptcy denial and DNTH’s Phase 3 trial progress for future opportunities."
}